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HIV-1 proteins, especially gp120 and Tat, elicit reactive oxygen species (ROS) and cause neuron apoptosis. We used antioxidant enzymes, Cu/
Zn superoxide dismutase (SOD1) and glutathione peroxidase (GPx1) to study signaling and neuroprotection from Tat-induced apoptosis. SOD1
converts superoxide to peroxide; GPx1 converts peroxide to water. Primary human neurons were transduced with SV40-derived vectors carrying
SOD1 and GPx1, then HIV-1 Tat protein was added. Both SV(SOD1) and SV(GPx1) delivered substantial transgene expression. Tat decreased
endogenous cellular, but not transduced, SOD1 and GPx1. Tat rapidly increased neuron [Ca2+]i, which effect was not altered by SV(SOD1) or SV
(GPx1). However, both vectors together blocked Tat-induced [Ca2+]i fluxes. Similarly, neither SV(SOD1) nor SV(GPx1) protected neurons from
Tat-induced apoptosis, but both vectors together did. Tat therefore activates multiple signaling pathways, in one of which superoxide acts as an
intermediate while the other utilizes peroxide. Gene delivery to protect neurons from Tat must therefore target both.
© 2007 Elsevier Inc. All rights reserved.Keywords: Cu/Zn superoxide dismutase; Glutathione peroxidase; SV40 vectors; Apoptosis signaling; Reactive oxygen species signalingIntroduction
HIV-1 transactivating (Tat) protein is secreted from micro-
glial cells of the brain and plays a important role in pathogenesis
of HIV-induced CNS disease and AIDS-associated dementia
complex (Rappaport et al., 1999; Ensoli et al., 1990). Tat
possesses several neurotoxic properties, as it acts directly on
neurons and trigger apoptosis by increasing reactive oxygen
species (ROS) (Choi et al., 2000; New et al., 1998; Perez et al.,
2001; Kruman et al., 1999; Shi et al., 1998). Tat binds to neurons
preferably using heparan sulfate proteoglycan (HSPG) and a low
density lipoprotein receptor (LRP) (Liu et al., 2000) and is then
translocated to the nucleus (Ma and Nath, 1997). It has also been
shown to bind to other receptors such as cell surface integrins
(Brake et al., 1990), and chemokine receptors such as CCR2,
CCR3, CCR5 and CXCR4 (Albini et al., 1998; Xiao et al.,
2000).
Tat increases cytosolic free calcium concentration ([Ca2+]i)
and consequent dysregulation of calcium homeostasis and⁎ Corresponding author. Fax: +1 215 503 1156.
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doi:10.1016/j.virol.2007.02.004apoptosis (Bonavia et al., 2001; Nath et al., 1996; Haughey et
al., 1999; Kruman et al., 1998). This increase in [Ca2+]i is an
early event in the Tat-induced apoptotic signaling and reflects
rapid release from intracellular cellular pools and influx from
extracellular fluid (Haughey et al., 1999; Bonavia et al., 2001).
The reactive oxygen species (ROS) that are increased by Tat
include superoxide (O2
−) and hydrogen peroxide (H2O2).
Superoxide dismutase (SOD) converts O2
− to H2O2 (Coyle
and Puttfarcken, 1993) which may then be converted to water
by catalase or glutathione peroxidase (GPx). In the later
reaction, reduced glutathione (GSH) is oxidized to GSSG.
Tat may also activate inducible nitric oxide synthase (iNOS)
to produce nitric oxide (NO) (Weis et al., 1993), which readily
binds superoxide to form the highly reactive species, peroxy-
nitrite (ONOO) (O2
−+NO→ONOO) (Beckman and Koppenol,
1996; Bonfoco et al., 1995; Chao et al., 1995). ONOO, a highly
reactive free radical, may bind to lipids, proteins and DNA, and
so in turn increases the likelihood of oxidant-related injury.
HIV-infected individuals have impaired antioxidant defenses
(Treitinger et al., 2000), which leads to elevated levels of ROS
(Piedimonte et al., 1997) and depletion of intracellular anti-
oxidants. In the present study we report that gene delivery of
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derived vectors can protect CNS neurons from Tat-induced
toxicity. SV40-derived vectors were used because they readily
transduce neurons in vitro and in vivo and have been effective in
studying gene transfer in neurons from HIV-1 in experimental
systems (Cordelier et al., 2003a, 2003b; Agrawal et al., 2006).
Neuroprotection from Tat-induced apoptosis was only observed
when both enzymes were delivered, and correlated with
decreased Tat-induced elevation of [Ca2+]i. These findings
have implications both for the understanding of Tat-induced
apoptosis and for potential gene delivery to treat HIV-1-
associated encephalopathy.
Results
Tat-induced apoptosis: dose–response in primary neurons
The optimal concentration of HIV-1 Tat to elicit apoptosis in
primary neurons was determined. Cells were incubated with 0, 1,
10 and 100 ng/ml of recombinant soluble Tat for 48 h (Fig. 1).
Apoptotic bodies were analyzed using terminal deoxynucleotidyl
transferase-mediated nick end labeling (TUNEL). Neurons were
identified by their expression of MAP-2. The intensity and
frequency of TUNEL+ cells were significantly higher (p<0.001)
as compared to untreated cultures. Increasing Tat concentration
above 10 ng/ml did not increase apoptosis significantly. Thus
10 ng/ml of Tat was used in all subsequent studies.
Tat-induced apoptosis: kinetics
The time course of Tat-induced apoptosis in primary neurons
was then examined. Cells were treated with Tat (10 ng/ml),
then analyzed for apoptosis beginning at 5 min after the addition
of Tat to cultures at regular intervals, extending up to 2 days
(Fig. 2). Significant (p<0.001) apoptosis was seen from the
assay point 30 min post-treatment. Maximum apoptosis was
noted beginning at 6 h post-treatment, when >90% of cells were
TUNEL+ (p<0.001, compared to no treatment control). Tat
exposure times of greater than 6 h did not increase the percentage
of apoptotic cells significantly (p>0.05). For all subsequent
experiments, neurons were incubated 10 ng/ml of Tat for 48 h.
Efficiency of recombinant SV(SOD1) and SV(GPx1) in
transducing neurons
Primary neurons were transduced with SV(SOD1) and SV
(GPx1) at multiplicity of infection (MOI)=10 on day 0, then
again at MOI=3 on days 3 and 5, for a cumulative MOI of 16.
This regimen is referred to as 10:3:3. Transgene expression was
assessed in transduced and control neurons 10 days after gene
delivery. Western analysis (not shown) confirmed our earlier
demonstration (Agrawal et al., 2006) that transduction with SV
(SOD1) and SV(GPx1) increased expression of SOD1 and
GPx1 in respectively transduced neuron populations.
Kinetic assay was also used to evaluate SOD1 and GPx1
enzymatic activities following transduction (Table 1). Cultures
treated with SV(SOD1) and/or SV(GPx1) showed markedlyand significantly increased activities of their respective
enzymes, compared to control cultures (p<0.05).
Protection of neurons from Tat-induced apoptosis by
transduction with SV(SOD1) and SV(GPx1)
Having established the optimum dose and scheduling of Tat
to produce maximal apoptosis in cultured neurons, and
characterizing the antioxidant enzyme constructs, we tested
whether delivery of SOD1 or GPx1, singly or in combination,
would protect neurons from Tat-induced programmed cell
death. Neurons were transduced with 10:3:3 regimen of SV
(SOD1) and/or SV(GPx1). Neurons were also transduced with
SV(HBS). Ten days after initial transduction, cells were
challenged by adding Tat(10 ng/ml) to cultures and apoptosis
was measured by TUNEL assay 2-days later. Apoptosis was
scored by counting TUNEL positive cells in six different 100×
fields per experiment. In control mock- or SV(HBS)-transduced
cultures 90–100% of cells were TUNEL positive. Background
levels of apoptosis in cells not challenged with Tat were less
than 3–5%, and were comparable among all experimental and
control groups (data not shown). Neurons transduced singly
with SV(SOD1) or SV(GPx1) were not protected from
apoptosis, compared to SV(HBS) transduced (Fig. 3). Interest-
ingly, double transduction with both SV(SOD1) and SV(GPx1)
significantly reduced apoptosis by >80% (p<0.001) as
compared to neurons transduced with the control rSV40 vector,
SV(HBS). Thus, combined transduction with both viruses
(SOD1 and GPx1), provided approximately 80% protection
from Tat-induced apoptosis, while transduction with either
vector individually did not prevent Tat-induced apoptosis.
Effects of SV(GPx1) and SV(SOD1) transduction and exposure
to Tat on SOD1 and GPx1 activity
Because combined transduction with rSV40s carrying SOD1
and GPx1 delivered strong protection from Tat-induced apopto-
sis, we asked whether treatment with Tat had any effect on
activity of these endogenous antioxidant enzymes. Neurons
were transduced with SV(SOD1) and/or SV(GPx1), or with the
control rSV40, SV(HBS), then exposed to Tat (10 ng/ml).
Transduction with SV(GPx1) alone or in combination with SV
(SOD1) increased GPx1 enzyme activity (Fig. 4A) as compared
to SV(HBS)-transduced cultures (p<0.001). Similarly trans-
duction with SV(SOD1), alone or in combination with SV
(GPx1), significantly and substantially increased SOD1 activity
(p<0.001) (Fig. 4B).
Neither vector influenced the activity of the opposite
enzyme. That is, transducing with SV(SOD1) had no significant
effect on GPx1 activity, and transducing with SV(GPx1) did not
significantly impact SOD1 activity (p>0.05).
Adding Tat to the cultures reduced the endogenous activity of
GPx1 in cells transduced with SV(HBS) or SV(SOD1)
(p<0.001) (Fig. 4A). Tat had no effect on the activity of GPx1
in SV(GPx1)-transduced cells. Adding Tat to cells transduced
with both SV(SOD1) and SV(GPx1) caused a slight increase in
GPx1 activity which was not statistically significant. Cells
Fig. 1. Apoptosis induced by HIV-Tat and dose response analysis with primary neurons. Recombinant HIV-1 Tat was added to primary human brain neuron cultures for
48 h at different concentrations from 1.0 ng/ml to 100 ng/ml. At the time of assay, cells were costained with anti-MAP-2 antibody. (a) Fluorescence micrographs
documenting expression of neuron marker MAP-2 expression and dose–response relationship between Tat concentration and neuron apoptosis. TUNEL positive cells
were also represented as average numbers of six different fields (b). Results represent average of three independent experiments.
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(SOD1), demonstrated significantly more (p<0.001) GPx1
activity, as compared to cells transduced with SV(HBS) or SV
(GPx1).
Adding Tat significantly (p<0.001) reduced SOD1 activity
in cultures that had been transduced with SV(HBS) or with SV
(GPx1) (Fig. 4B). Tat slightly but significantly increased SOD1
activity (p<0.001) when added to cells transduced with SV
(SOD1) alone, and slightly but significantly decreased SOD1activity in cultures transduced with a combination of SV(GPx1)
and SV(SOD1) (p<0.001).
Effects of SV(SOD1) and SV(GPx1) on Tat-induced cytosol
calcium fluxes
Tat increases [Ca2+]i in neurons (Haughey and Mattson,
2002). FURA-2AM-loaded neurons were exposed to recombi-
nant Tat (10 ng/ml) at 60 s. Cytosol free calcium concentration
Fig. 2. Time course of apoptosis induced by HIV-1 Tat in primary neurons. Recombinant HIV-1 Tat at 10 ng/ml was added to cultures of primary human neurons for
varying times from 5 min to 2 days. (a) TUNEL fluorescence and corresponding MAP-2 staining of cultured neurons. DAPI staining is shown below. TUNEL positive
cells are also represented: (b) as average numbers of six different fields.
465L. Agrawal et al. / Virology 363 (2007) 462–472changes were measured using a split-beam photometer for 300 s.
Adding Tat caused a sustained increase in [Ca2+]i, through the
180 s of the assay in neurons transduced with the control rSV40,
SV(HBS) (Fig. 5). Prior transduction with either SV(SOD1) or
SV(GPx1) individually did not alter Tat-induced Ca2+ transients.
However, cotransduction with both SV(SOD1) and SV(GPx1)
almost completely prevented Tat-mediated increases in intra-
cellular [Ca2+]i (Fig. 5). These data suggest that Tat signaling to
increase [Ca2+]imay involve two pathways, and that one of these
pathways is inhibited by SOD1while the other one is blocked by
GPx1. Thus, O2
− and H2O2 may act as early signaling
intermediates that transduce Tat-initiated signals to cellular
calcium stores and calcium channels.
Treatment with Tat decreases cellular levels of reduced
glutathione (GSH)
Tat has been shown to decrease the intracellular pool of
reduced glutathione (GSH) (Price et al., 2006). This is expected,since GSH is converted to its oxidized form GSSG, when GPx1
detoxifies H2O2. We tested whether transducing neurons with
SV(SOD1) or SV(GPx1) had any effect on Tat-mediated
reduction in GSH levels. GSH levels in cells transduced with
SV(SOD1) and SV(GPx1) were similar to levels in control cells
(p>0.05). We confirmed that Tat treatment of neurons
significantly reduced cellular GSH (p<0.001) (Fig. 6). GSH
pools in neurons transduced with SV(SOD1) or SV(GPx1) and
then treated with Tat were still sensitive to Tat treatment, and
were similar to levels in control-treated neurons (p>0.05). Cells
that were doubly transduced and exposed to Tat had slightly
more GSH than did control Tat-exposed cells, but this increase
was not statistically significant (p>0.05).
Discussion
Our studies show that HIV-1 Tat induces apoptosis in
primary neuron cultures in a dose- and time-dependent manner.
The 10 ng/ml Tat concentration that we used for most of our
Table 1










SV(GPx1) GPx1 908±23 p<0.05
SV(HBS) SOD1 1609±16
SV(SOD1) SOD1 5788±31 p<0.05
Effectiveness of transduction with SV(SOD1) and SV(GPx1) in delivering
enzyme expression and activity in neurons. Transduction with both SV(SOD1)
and SV(GPx1) vectors was performed in neuron cultures as described in
Materials and methods. Control neuron cultures were treated with SV(HBS).
Enzyme activity was measured by kinetic analysis as described in Materials
and methods. Neurons were transduced with respective viruses and analyzed
using commercial SOD1 and GPx1 detection kits, according to the manufac-
turer's instructions.
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infected patients (Westendorp et al., 1995). We also demon-
strate, by gene transfer of SOD1 and GPx1, that reactive oxygen
species are obligatory for Tat-induced apoptosis to occur. Other
investigators have reported that Tat induces neuron cell death
via reactive oxygen intermediates both in tissue culture and in
vivo ((Aksenov et al., 2001; Bonavia et al., 2001; Kendall et al.,
2005; Kruman et al., 1998; Singh et al., 2005; Bansal et al.,
2000).
An early event in HIV Tat-induced neuronal apoptosis is
elevation of cytosol free calcium ([Ca2+]i) (Shi et al., 1998). We
saw a rapid increase in [Ca2+]i after treatment with Tat, as is
characteristic of release of Ca2+ from intracellular stores. That
response to Tat follows sigmoidal kinetics with [Ca2+]i reaching
saturating levels rapidly and maintaining those calcium levels
for the duration of the time studied (5 min). Although one study
using cultured human cortical neurons reported that Tat-induced
increases in cytosol calcium returned to baseline levels within
minutes (Ma and Nath, 1997), our results are more similar to
other reports that describe sustained changes in [Ca2+]i
(Bonavia et al., 2001; Perez et al., 2001; Nath et al., 1996;
Haughey et al., 2001; Kruman and Mattson, 1999).
Moreover we also found that neurons transduced with SV
(HBS) and then treated with Tat showed a biphasic [Ca2+]i
response: a steep initial response was followed by a slower and
more protracted second response. Transduction with SV(SOD1)
or SV(GPx1) caused a monophasic response, steeper than
either. This suggests a duality in Tat-responsiveness that may
reflect the activities of different signaling pathways, multiple
types of calcium release mechanisms, variable mitochondrial
polarization (Perry et al., 2005) and/or diverse cell membrane
channels.
The nature of the involvement of ROS in this process has not
yet been clarified, however. Until recently, ROS were largely
thought of as effector molecules in cell death, generated mainly
by the mitochondrial electron transport chain. Whether alone, or
following interaction with NO to form ONOO, ROS were seen
as causing cell damage and death by oxidizing proteins, lipids
and DNA.It is now clear that ROS and RNS are important signaling
intermediates in many receptor-driven and other processes
(Matsuzawa and Ichijo, 2005; Stone and Yang, 2006).
Production of superoxide, peroxide and other oxygen radicals
occurs at the cell membrane and is activated by receptor-
triggered enzymes such as NADPH oxidase (NOX) (Finkel,
2003). These species and their nitrogen-containing relatives
bind to sulfhydryl groups at enzymes' active sites, either
activating or inactivating the target. The specificity of the
interaction and the nature of the result depend in part on the
magnitude and duration of the increase in ROS. Transient,
relatively low level exposure to O2
− or to H2O2 often activates
cell proliferation (Matsuzawa and Ichijo, 2005). Longer and
greater exposures may have the opposite effect, leading to
apoptosis. Signaling in the former setting is often mediated by
the ERK family of MAP kinases, while the latter signaling may
be mediated by p38 and JNK groups of MAP kinases,
particularly apoptosis signaling kinase-1 (ASK1) (Behar et al.,
2001; Matsuzawa and Ichijo, 2005).
Several basic findings reported here suggest that O2
− andH2O2
transduce Tat-induced signals. First, O2
− and H2O2 clearly act
upstream of the calcium release phase of the signaling process, as
combined SOD1 and GPx1 block Tat-elicited calcium release
and apoptosis. As well, calcium release occurs within seconds,
while TUNELpositivity peaks around 6 to 12 h. This chronology
is most consistent with involvement of O2
− and H2O2 in
transduction, rather than solely as effectors, of apoptosis.
The fact that inhibiting either O2
− or H2O2 separately (with
SOD1 and GPx1 respectively) does not protect from apoptosis
triggered by Tat further suggests that these ROS are inter-
mediates in different Tat-activated pathways. This is different
from HIV-1 gp120-induced apoptosis, in which transduction
with SV(SOD1) or SV(GPx1) is protective (Agrawal et al.,
2006). The high level of protection observed when SOD1 and
GPx1 are combined suggests that other signaling pathways that
do not involve O2
− or H2O2 account for little or none of the Tat-
activated apoptosis observed. There are several other signaling
cascades in which O2
− and H2O2 are known to be part of separate
pathways (Zheng and Storz, 2000; Devadas et al., 2002).
Tat reportedly activates the TNFα promoter in microglia,
macrophages and T lymphocytes, stimulating production of
TNFα and leading secondarily to neuronal apoptosis (Philippon
et al., 1994; Mayne et al., 1998; Sawaya et al., 1998; Darbinian
et al., 2001), which can be blocked in part by soluble TNF
receptor (TNFR) protein (Williams et al., 2005). Furthermore,
Tat-induced apoptosis of lymphocytes involves activation of
CD95 (Fas receptor, FasR) (Gulow et al., 2005), and a report of
brain astrocyte apoptosis elicited by HIV-infected macrophages
implicates CD95 as well (Ehret et al., 1996). Although CD95
has not been reported to participate in Tat-induced neuron
apoptosis, its involvement in HIV-1- and Tat-triggered apopto-
sis in other cell types raises that possibility. Thus, multiple
pathways, including TNFR, FasR and others may also signal
Tat-induced neuronal apoptosis. ROS have been implicated in
signaling pathways triggered by activation of TNFR and FasR
(Matsuzawa and Ichijo, 2005;Shakibaei et al., 2005). O2
− and
H2O2 may thus take part in distinct separate signaling pathways,
Fig. 3. Combined delivery of SOD1 and GPx1 by rSV40s protects neurons from Tat-induced apoptosis. Primary human neuron cultures were transduced with
SV(SOD1) and/or SV(GPx1), or a control vector, SV(HBS). The cells were maintained for 10 days after initial transduction in DMEM supplemented with 2% fetal
bovine serum, following which recombinant HIV-1 Tat [10 ng/ml] was added for 2 days. (a) Representative fluorescence micrographs (together with the DAPI stained
frames of the same fields) are shown test cultures treated with one or both vectors, and for control (SV(HBS))-transduced cultures. (b) average total numbers of
TUNEL-positive cells as a function of vectors used to transduce the neurons. Statistical significance, measured by the ANOVA, is as indicated.
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neurotoxicity.
Exposing neurons to Tat decreases SOD1 and GPx1 activity.
Transduction with SV(SOD1), alone or in combination with SV
(GPx1), increases baseline SOD1 activity and renders SOD1
activity impervious to Tat. The same applies to transduction
with SV(GPx1) and GPx1. Decreased GPx activity has been
reported following exposure of brain endothelial cells to Tat
(Price et al., 2005). The mechanism underlying this observation
is unclear. In a slightly different cell system, Tat was shown toreduce GPx transcripts (Richard et al., 2001; Price et al., 2005).
The effects of Tat on SOD1 are unexpected, however. Tat
lowers levels of mRNA for MnSOD (SOD2), a mitochondrial
enzyme. It does this at least in part by altering the population of
Sp-family transcription factors that bind to the SOD2 promoter:
the presence of Tat favors the binding to Sp3 to the SOD2
promoter, rather than Sp1. The former is a far weaker
transcriptional activator for this promoter (Seve et al., 1999;
Marecki et al., 2004; Porntadavity et al., 2005). Other
investigators report that Tat modifies histone deacetylase
Fig. 4. SV(SOD1) or SV(GPx1) deliver Tat-resistant GPx1 and SOD1 activity.
Primary neuron cultures were treated with SV(SOD1) and/or SV(GPx1), or with
SV(HBS) (control vector). Parallel cultures either received HIV-1 Tat at 10 ng/
ml, or no additions. Activities of both GPx1(A) and SOD1(B) were measured
using a kinetic spectrophotometer as described in Materials and methods.
Statistical significance between No Tat (■) and Tat treated (□) samples in each
individual group is indicated by (*). Significant differences in GPx1 and SOD1
activity between different groups in No Tat treated samples (■) are represented
as (#). Statistical significance, measured by the ANOVA, is as indicated.
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diverse experimental systems, including many different cell
types and routes of exposure to Tat. Our finding of decreased
SOD1 activity in primary neurons is unique. One other group
reported using HeLa cells stably transfected with a Tat
expression construct showed that Tat did not affect SOD1
levels (Flores et al., 1993) (We did not study SOD2).
Unlike endogenous SOD1 and GPx1, the elevated levels of
SOD1 and GPx1 in their respective transduced cells were not
decreased by exposure to Tat. Although we have not specifically
examined the mechanism(s) of Tat's effects on neuronal SOD1
and GPx1 activity, it is possible, as with SOD2 in HeLa cells,
that Tat alters endogenous promoter activity. Our use of the
RSV-LTR to drive transgene expression in SV(SOD1) and SV
(GPx1) may thus protect these enzymes from transcriptional
downregulation by Tat. The small increase in SOD1 activity in
Tat-treated, SV(SOD1)-transduced neurons, and in GPx1
activity in dual-transduced neurons, may involve slight
upregulation of RSV-LTR activity.
Tat also decreases levels of reduced glutathione (GSH)
available to relieve oxidant stress. Interestingly, protection from
Tat-induced oxidant load by SOD1 or GPx1 does not increasecellular GSH concentrations. Considerable work has been done
in this vein in other experimental systems (Brune et al., 1999;
Brune, 2005), and it seems that as long as the effectiveness of
GSH as a free radical scavenger is not impaired, reduced GSH
levels do not imply a functional deficit in glutathione-related
free radical detoxifying activity.
HIV-1 infection in the CNS remains a considerable problem,
one that has been largely untouched by therapy, genetic or
otherwise. We have studied rSV40-mediated gene transfer of
SOD1 and GPx1 as an approach to protecting human neurons
from apoptosis induced by HIV-1 Tat. Neuroprotection from
apoptosis caused by Tat requires detoxification of both O2
− and
H2O2 via SOD1 and GPx1. Combining SV(SOD1) plus SV
(GPx1) provides such protection. These studies thus have
implications for both our understanding of the pathogenesis of
HIV-related CNS disease and for the development of treatment
strategies.
Materials and methods
Plasmids and viral expression constructs
Human Cu/Zn SOD (SOD1), and GPx1 and cDNAs were
subcloned in to pT7[RSVLTR], in which their expression is
driven by the Rous Sarcoma Virus long terminal repeat (RSV-
LTR) as a promoter. SV(HBS), which encodes Hepatitis B
surface antigen (HBsAg) (Kondo et al., 1998), was used as
negative control rSV40 for these experiments. Generation of
recombinant SV40 vectors has been reported in detail (Strayer
et al., 2001). Briefly, recombinant viral genomes were
transfected into COS-7 cells, which supply all SV-40 genes
needed for virus packaging. Recombinant viral stocks were
prepared as cell lysates and band purified using sucrose cushion
(Strayer et al., 2001). Virus stocks were titered by quantitative
PCR (Q-PCR, Stratagene, Inc.) (Strayer et al., 2006). SV40
vectors were designed by deleting large T antigen, plus a
variable amount of the remainder of the SV40 genome from
cloned wt SV40 genomes. SV40 vectors infect almost all cell
types including HSC, lymphocytes, macrophages, dendritic
cells, and primary neurons. Vector DNA integrates into cellular
DNA, yielding permanent gene delivery. They thus can be
administered repeatedly without loss of transduction efficiency.
Primary human fetal neuronal cells
Neurons were isolated from human fetal brain as described
previously (Jana and Pahan, 2004). Briefly, fetal brain (from the
Human Fetal Tissue Bank, Albert Einstein College of Medicine,
Bronx, NY) was homogenized in Hanks Balanced Salt Solution
(HBSS) Ca2+ and Mg2+ free containing 0.05% Trypsin and 100
U of DNase. Mixed brain cultures were passed through 170 μm
Nylon mesh, then plated in poly-D-lysine coated 24 well plates
or 4-chamber slides. Non-adherent cells were removed by
washing with DMEM/F-12 (Invitrogen, Carlsbad, CA). Adher-
ent neuronal cultures were treated with cytosine arabinoside (ara
C-1 μM) for 2 weeks. The neuronal nature of these cells was
verified by immunostaining with MAP-2 antibody.
Fig. 5. Tat-induced calcium signaling in neurons is prevented by combined transduction with SV(SOD1)+SV(GPx1). Neurons were transduced as in Fig. 4 legend,
loaded with FURA-2AM and analyzed using split beam photometry after addition of HIV-1 Tat (10 ng/ml) as described in Materials and methods. Absorbance was
measured at 340 and 380 nm. Measurement was done for 300 s with a total of 100 frames (1 frame=3 s). Tat was added at 1 min (arrow, frame 20). The increase in
intracellular calciumwas seen as change in fluorescence and color fromgreen to yellow after treatmentwith Tat.Data represent average of three independent experiments.
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Neurons obtained from the fetal brain were plated at a
density of 0.1×106 cells/well in a 4-chamber slide and wereFig. 6. Glutathione levels in neurons after transduction with SV(GPx1) and/or
SV(SOD1) and exposure to Tat. Neurons were transduced with SV(SOD1) and/
or SV(GPx1) or (negative control) SV(HBS), then treated with Tat (10 ng/ml).
GSH concentration was measured as described in Materials and methods.
*p<0.001 compared to parallel cultures without added Tat.treated with different concentrations of Tat (NIH AIDS
Reference Reagent Repository) for varying amounts of time.
They were then analyzed for apoptosis, which was measured by
the TUNEL assay (Cell Death Detection Kit, Roche, Indiana-
polis, IN, used according to manufacturer's instructions). The
mean sum fluorescence intensity of TUNEL positive cells was
calculated using IP Lab software and analyzed on fluorescence
imaging/microscope (Olympus IX70).
Transduction and challenge studies
Primary neurons were transduced with SV40-derived viruses
SV(SOD1) and SV(GPx1) either singly or in combination on
days 0, 3 and 5 at virus to cell ratio (MOI) of 10, 3 and 3,
respectively. The cells were tested for transgene expression by
Western analysis and immunostaining which showed >90%
transduction efficiency(data not shown). The cells were
maintained for 10 days in DMEM supplemented with 2%
fetal bovine serum. The transduced and mock-transduced cells
showed the same degree of viability (>95%).
Immunostaining
Cells were grown in 4-chamber slides treated with poly-D-
lysine and matrigel. At the indicated times post-transduction,
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permeabilized with 0.1% Triton X-100 in sodium citrate
buffer. Nonspecific binding was blocked by treating cells with
normal serum from the animal species in which the secondary
antibody was raised, then immunostained with either anti-
MAP-2 (1:50) for 1 h on ice. After extensive washes in
phosphate buffered saline (PBS) containing 1% bovine serum
albumin (BSA), secondary antibodies conjugated with
rhodamine (TRITC, Sigma Chemicals, St. Louis, MO) were
added. The cells were washed and analyzed on fluorescence
imaging/microscope (Olympus IX70).
Measurement of cytoplasmic calcium flux
Fluorescence imaging of the intracellular dye fura-2
(Molecular Probes, Eugene, OR) was used for quantification
of [Ca2+]i in individual fetal neurons (Strayer et al., 1996).
Neurons were incubated with 5 μM acetoxymethylester form
of fura-2 (fura-2 AM) (Molecular Probes, Carlsbad, CA) in
loading buffer containing (120 mM NaCl, 5 mM KCl,
20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 6 mM Glucose,
1 mM glutamine, 0.1% BSA) for 1 h at 37 °C. The cells
were then washed ×2 in loading buffer without fura-2AM
and left for 15 min at RT for de-esterification. Cells were
imaged on Olympus fluoroscence microscope and the ratio of
fluorescence emission using two different excitation wave-
lengths (340 and 380 nm) was measured for at least 10–15
cells in the microscopic field in four different independent
experiments.
Kinetic assays for GSH
GSH activity
Total glutathione activity in Tat-treated and rSV-40 trans-
duced cells was determined using Glutathione kit (Calbiochem,
San Diego, CA). Mercaptans (RSH) in the sample form a
complex (thioether) with the reagent R1(4-chloro-1-methyl-7-
trifluoromethyl-quilonium methylsulfate). The second step is a
β-elimination reaction mediated by 30% NaOH which
specifically transforms the substitution product obtained with
GSH into chromophoric thione with a maximal absorbance at
400 nm. The concentration of [GSH] was calculated using the
formula:
½GSH ¼ fðA A0Þ=A Ig  D
where [GSH] is the initial glutathione concentration in the sam-
ple, expressed as molar concentration; A and A0 are the absor-
bances measured in the presence and absence of the sample; A is
the apparent molar extinction coefficient of the product
measured at 400 nm; I is the optical path (cm); D is the dilution
factor for the sample.Kinetic assays for SOD1 and GPx1
Kinetic assays for these enzymes have been earlier described
(Agrawal et al., 2006).Statistical analysis
Statistical analysis was performed using ANOVA for
comparison between multiple groups.
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